Literature DB >> 1554831

Pharmacokinetics of systemically administered antibiotics in patients with thermal injury.

B A Boucher1, D A Kuhl, W L Hickerson.   

Abstract

Patients who sustain thermal injury may require adjustments of antibiotic dosing because of pharmacokinetic alterations and pathological changes that occur in this patient subset. In general, studies of gentamicin, tobramycin, and amikacin have demonstrated lower elimination half-lives in burn patients than in nonburn patients and healthy volunteers. Other studies have shown a strong correlation between vancomycin clearance and creatinine clearance and the need for higher vancomycin dosages for burn patients than for nonburn patients. Studies of ceftazidime, ticarcillin, enoxacin, and aztreonam have shown increases in the volume of distribution or decreases in the maximum concentration achieved. Total and renal drug clearance of aztreonam was highly correlated with creatinine clearance. With imipenem, the half-life, clearance, and volume of distribution observed in burn patients were not significantly different from those in nonburn patients, although substantial interpatient variability existed. Imipenem clearance was significantly correlated with creatinine clearance. Individualization of antibiotic therapy for burn patients is recommended with use of measured serum concentrations of the antibiotic or creatinine clearance as an estimate of renal function.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1554831     DOI: 10.1093/clinids/14.2.458

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  16 in total

Review 1.  Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.

Authors:  P S McKinnon; S L Davis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-10       Impact factor: 3.267

Review 2.  Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness.

Authors:  Rina Mehrotra; Raffaele De Gaudio; Mark Palazzo
Journal:  Intensive Care Med       Date:  2004-11-05       Impact factor: 17.440

3.  Population pharmacokinetics of arbekacin in burn patients.

Authors:  Jong Hyun Kim; Hyon-Oh Lah; Dong-Seok Yim
Journal:  Eur J Clin Pharmacol       Date:  2008-06       Impact factor: 2.953

4.  Fluconazole pharmacokinetics in burn patients.

Authors:  B A Boucher; S R King; H L Wandschneider; W L Hickerson; S D Hanes; V L Herring; T W Canada; M M Hess
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

5.  Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units.

Authors:  K Vandewoude; D Vogelaers; J Decruyenaere; P Jaqmin; K De Beule; A Van Peer; R Woestenborghs; K Groen; F Colardyn
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

6.  Ciprofloxacin pharmacokinetics in burn patients.

Authors:  J C Garrelts; G Jost; S F Kowalsky; G J Krol; J T Lettieri
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

7.  Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis.

Authors:  Lyndsay M van de Vijsel; Sandra A N Walker; Scott E Walker; Sharon Yamashita; Andrew Simor; Michelle Hladunewich
Journal:  Can J Hosp Pharm       Date:  2010-05

Review 8.  Clinical Pharmacokinetics of Amikacin in Pediatric Patients: A Comprehensive Review of Population Pharmacokinetic Analyses.

Authors:  Sílvia M Illamola; Catherine M Sherwin; J G Coen van Hasselt
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

9.  Pharmacokinetics of cefepime in patients with thermal burn injury.

Authors:  C R Bonapace; R L White; L V Friedrich; E D Norcross; J A Bosso
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

10.  Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury.

Authors:  John F Mohr; Luis Ostrosky-Zeichner; David J Wainright; Donald H Parks; Timothy C Hollenbeck; Charles D Ericsson
Journal:  Antimicrob Agents Chemother       Date:  2008-02-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.